Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 14, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-11-06
DOI
10.3389/fphar.2023.1245642
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study
- (2023) Adam Goldman et al. Cardiovascular Diabetology
- Why hospital-based healthcare professionals do not report adverse drug reactions: a mixed methods study using the Theoretical Domains Framework
- (2022) Raymond Li et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
- (2022) Gabriella di Mauro et al. Pharmaceuticals
- SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study
- (2022) Celestino Sardu et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
- (2022) Annamaria Mascolo et al. Frontiers in Cardiovascular Medicine
- Managing older patients with heart failure calls for a holistic approach
- (2021) Julia H.I. Wiersinga et al. ESC Heart Failure
- Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States
- (2021) Veer Sangha et al. Circulation-Cardiovascular Quality and Outcomes
- Current and future therapeutic perspective in chronic heart failure
- (2021) Annamaria Mascolo et al. PHARMACOLOGICAL RESEARCH
- SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
- (2021) Annamaria Mascolo et al. PHARMACOLOGICAL RESEARCH
- Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes
- (2021) Min Zhuo et al. JAMA Network Open
- Impact of an early mobilization protocol on outcomes in trauma patients admitted to the intensive care unit
- (2020) Sherry Jenna Coles et al. Journal of Trauma and Acute Care Surgery
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study
- (2020) Bin Zhao et al. Journal of Diabetes Investigation
- Fracture Risk After Initiation of Use of Canagliflozin
- (2019) Michael Fralick et al. ANNALS OF INTERNAL MEDICINE
- Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
- (2019) Yangli Ye et al. Frontiers in Pharmacology
- Hypertension Management in Older and Frail Older Patients
- (2019) Athanase Benetos et al. CIRCULATION RESEARCH
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
- (2019) Jiahua Li et al. Clinical Kidney Journal
- Sodium‐glucose co‐transporter 2 inhibitors and the risk of fractures: A propensity score‐matched cohort study
- (2019) Sruthi Adimadhyam et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial
- (2019) Katrine Hygum et al. BONE
- Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study
- (2018) Wen-Hsuan Hou et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Adverse effects of SGLT2 inhibitors on bone health
- (2018) Jenny E. Blau et al. Nature Reviews Nephrology
- Diabetes pharmacotherapy and effects on the musculoskeletal system
- (2018) Evangelia Kalaitzoglou et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Association of Cardiovascular Disorders and Falls: A Systematic Review
- (2016) Sofie Jansen et al. Journal of the American Medical Directors Association
- Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
- (2015) Ofri Mosenzon et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
- (2014) Bruce Neal et al. DIABETES CARE
- Morbus Diureticus in the Elderly: Epidemic Overuse of a Widely Applied Group of Drugs
- (2013) Martin Wehling Journal of the American Medical Directors Association
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials
- (2011) M. Monami et al. DIABETES CARE
- Risk Factors for Falls in Community-dwelling Older People
- (2010) Silvia Deandrea et al. EPIDEMIOLOGY
- Falls: Epidemiology, pathophysiology, and relationship to fracture
- (2008) Sarah D. Berry et al. Current Osteoporosis Reports
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now